Skip to main content

Advertisement

SpringerLink
Log in

Randomized Controlled Trial: 4 Month versus 6 Month Monitoring of HIV-infected Patients on Highly Active Antiretroviral Therapy

  • Original Paper
  • Published:
Journal of Community Health Aims and scope Submit manuscript

Abstract

As HIV treatment becomes more widely available and efficacious, and persons with HIV live longer, considerations for the financial and healthcare impact are of important. The best interval for routine HIV monitoring has been identified as area in which gaps in knowledge exist. The goal of this study is to determine the impact of changing scheduled follow up care for persons with HIV from a 4 to 6 months interval. HIV infected adults with a CD4 count ≥250 cells/μl, and an undetectable HIV viral load (VL) by an ultrasensitive assay for at least 1 year were randomized to routine HIV care at either a 4 or 6 months interval. Subjects were monitored for virological failure, adherence and quality of life (QOL). 142 subjects were enrolled and completed study protocol. Two subjects in the 6 months arm developed virological failure, p value = 0.5. There was no difference in adherence, or QOL scores. Subjects in the 4 months arm had higher rates of HIV visits (8.5/100 vs. 5.2/100 person months, p = 0.01) and non-HIV related visits (9.4/100 vs. 6.0/100 person months, p = 0.01) and were more likely to change antiretroviral regimen (34.8 vs. 15.8 %, p = 0.01). Despite strict inclusion criteria in this relatively short follow up time, 2/142 (1.4 %) subjects developed virological failure and many more had transient detectable VL. While not statistically significant a larger study with longer follow up is needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Palella, F. J., Delaney, K. M., Moorman, A. C., et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine, 338, 853–860.

    Article  PubMed  Google Scholar 

  2. Centers for Disease Control and Prevention. HIV Surveillance Report, 2012, Vol. 24. http://www.cdc.gov/hiv/library/reports/surveillance. Published November 2014. Accessed 22 Jan 2015.

  3. Harrison, K. M., Song, R., & Zhang, X. (2010). Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. Journal of Acquired Immune Deficiency Syndromes, 53, 124–130.

    Article  PubMed  Google Scholar 

  4. The Antiretroviral Therapy Cohort Collaboration. (2008). Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet, 372, 293–299.

    Article  PubMed Central  Google Scholar 

  5. Cooper, D. A. (2008). Life and death in the cART era. Lancet, 372, 266–267.

    Article  PubMed  Google Scholar 

  6. Antiretroviral Therapy Cohort Collaboration, Zwahlen, M., Harris, R., May, M., Hogg, R., Costagliola, D., et al. (2009). Mortality of HIV-infected patients starting potent antiretroviral therapy: Comparison with the general population in nine industrialized countries. International Journal of Epidemiology, 38(6), 1624–1633. doi:10.1093/ije/dyp306.

  7. Lohse, N., Hansen, A. E., Pedersen, G., Kronborg, G., et al. (2007). Survival of persons with and without HIV infection in Denmark, 1995–2005. Annals of Internal Medicine, 146, 87–95.

    Article  PubMed  Google Scholar 

  8. Aberg, J. A., Gallant, J. E., Ghanem, K. G., Emmanuel, P., Zingman, B. S., & Horberg, M. A. (2013). Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the infectious diseases society of America. Clinical Infectious Diseases, 2014(58), e1–e34.

    Google Scholar 

  9. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0. Accessed 7 July 2015.

  10. Günthard, H. F., Aberg, J. A., Eron, J. J., Hoy, J. F., Telenti, A., Benson, C. A., et al. (2014). Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA, 312, 410–425.

    Article  PubMed  Google Scholar 

  11. Walensky, R. P., Freedberg, K. A., Weinstein, M. C., & Paltiel, A. D. (2007). Cost-effectiveness of HIV testing and treatment in the United States. Clinical Infectious Diseases, 45(Suppl 4), S248–S254.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Schackman, B. R., Gebo, K. A., Walensky, R. P., Losina, E., Muccio, T., Sax, P. E., et al. (2006). The lifetime cost of current human immunodeficiency virus care in the United States. Medical Care, 44(11), 990–997.

    Article  PubMed  Google Scholar 

  13. Buscher, A. L., & Giordano, T. P. (2010). Gaps in knowledge in caring for HIV survivors long-term. JAMA, 304, 340–341.

    Article  CAS  PubMed  Google Scholar 

  14. Reekie, J., Mocroft, A., Sambatakou, H., EuroSIDA Study Group, et al. (2008). Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure? AIDS, 22, 2381–2390.

    Article  PubMed  Google Scholar 

  15. Goetz, M. B., Ferguson, M. R., Han, X., McMillian, G., et al. (2006). Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure. Journal of Acquired Immune Deficiency Syndromes, 43, 541–549.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Kendall, M. A., Andersen, J. W., & van Der, H. C. (2006). A reduced frequency visit schedule underreports adverse events that resulted in dose modification or treatment discontinuations in HIV/AIDS clinical trials: ACTG DACS 207. Contemporary Clinical Trials, 27, 287–294.

    Article  PubMed  Google Scholar 

  17. Julian, F. S., Martin, P., & Erickson, S. R. (2010). Validation of the special projects of national significance adherence tool in HIV/AIDS patients. The Annals of Pharmacotherapy, 44, 1003–1009.

    Article  PubMed  Google Scholar 

  18. Medical outcomes study HIV health survey (MOS-HIV). John Hopkins Bloomberg School of Public Health. http://www.jhsph.edu/mos-hiv/scoring.html.

  19. Norman, P., Bennett, P., Smith, C., & Murphy, S. (1998). Health locus of control and health behaviour. Journal of Health Psychology, 3(2), 171–180.

    Article  CAS  PubMed  Google Scholar 

  20. Bonner, K., Mezochow, A., Roberts, T., Ford, N., & Cohn, J. (2013). Viral load monitoring as a tool to reinforce adherence: A systematic review. JAIDS Journal of Acquired Immune Deficiency Syndromes, 64(1), 74–78.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine, University of South Carolina, Columbia, SC, USA

    Sharon Weissman & Shana Dykema

  2. School of Public Health, West Virginia Univeristy, Morgantown, WV, USA

    Sarah Singh & R. David Parker

Authors
  1. Sharon Weissman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shana Dykema
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. David Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. David Parker.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weissman, S., Singh, S., Dykema, S. et al. Randomized Controlled Trial: 4 Month versus 6 Month Monitoring of HIV-infected Patients on Highly Active Antiretroviral Therapy. J Community Health 41, 1044–1048 (2016). https://doi.org/10.1007/s10900-016-0188-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10900-016-0188-4

Keywords

Search

Navigation